OS after subdivision, where pT1 was 89.9%, while cT1/pT3a correlated with pT2 (79.8% and 83.1%, p[0.640) and cT2/pT3a correlated with cT3a/pT3a 67. 0% and 64.2%; p[0.893).
INTRODUCTION AND OBJECTIVES:
Criteria for staging of T1 renal tumors into T1a ( 4cm) and T1b (4cm< and 7cm) have remained unchanged since 1997. Advancements in tumor biology have led to great understanding of the heterogeneous potential of T1 renal tumors. We hypothesized that a three-tier classification may more rationally risk stratify T1 renal masses than the current T1a/T1b system. METHODS: Multicenter (UCSD, Emory, Fox Chase Cancer Center, Ospadele San Raffaele) retrospective analysis of patients with cT1 renal cell carcinoma (RCC) undergoing partial or radical nephrectomy. Patients were stratified by tumor size into three groups cT1a ( 2cm, very low risk), cT1b (2cm< and 5cm, low risk), and cT1c (5cm< and 7cm, intermediate risk). Primary outcome was recurrencefree survival (RFS). Secondary outcome was overall survival (OS). Multivariable Cox Regression analysis (MVA) and Kaplan-Meier analyses (KMA) were utilized for outcomes.
RESULTS: 4710 patients were stratified into proposed T1 groups (T1a [856, T1b[2909, T1c[945; median follow-up 39 months) . Mean age increased with tumor size (T1a 57.4 yrs, T1b 60.1 yrs, T1c 70.0 yrs, p<0.001) as did total RENAL scores (T1a 6.5, T1b 7.6, T1c 9.0, p<0.001). For cT1a, cT1b and cT1c tumors, KMA revealed 5 year RFS of 95.7%, 90.8%, and 80.8%, (p<0.001; Figure 1a ) and 5 year OS of 89.3%, 85.5%, and 73.3% (p[<0.001, Figure 1b) gene) are managed at our institution based on genotype. Active surveillance (AS) until 3 cm is employed for VHL, FLCN, and METaltered tumors, while immediate surgical resection is used for FH and SDHB tumors. BAP1-associated tumors are a more recently described entity that is associated with high grade, high stage RCC, and while we do not routinely perform AS for these lesions, some patients have undergone a period of AS prior to being diagnosed with BAP1 alterations. We sought to characterize the growth of genetically-defined tumors during AS.
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METHODS: Patients managed on prospective National Cancer Institute Institutional Review-approved protocols with germline alterations in VHL, FLCN, MET, and BAP1 and multiple cross-
